{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T23:04:38Z","timestamp":1776035078312,"version":"3.50.1"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202103108"],"award-info":[{"award-number":["tsqn202103108"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2804400"],"award-info":[{"award-number":["2022YFC2804400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejmech.2023.115128","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T08:47:42Z","timestamp":1674722862000},"page":"115128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Overview of the development of HBV small molecule inhibitors"],"prefix":"10.1016","volume":"249","author":[{"given":"Huihui","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1650-1761","authenticated-orcid":false,"given":"Jinfei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115128_bib1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115128_bib2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12072-017-9829-7","article-title":"Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread","volume":"11","author":"Karayiannis","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ejmech.2023.115128_bib3","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1080\/21645515.2015.1132129","article-title":"Viral hepatitis vaccination during pregnancy","volume":"12","author":"Zhao","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.ejmech.2023.115128_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/v12030285","article-title":"The interactions between HBV and the innate immunity of hepatocytes","volume":"12","author":"Megahed","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115128_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/humupd\/dmaa034","article-title":"Molecular genetics of infertility: loss-of-function mutations in humans and corresponding knockout\/mutated mice","volume":"27","author":"Jiao","year":"2021","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.ejmech.2023.115128_bib6","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1016\/j.cub.2020.09.050","article-title":"Elevated temperatures cause transposon-associated DNA damage in C. elegans spermatocytes","volume":"30","author":"Kurhanewicz","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2023.115128_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12958-015-0032-1","article-title":"A unique view on male infertility around the globe","volume":"13","author":"Agarwal","year":"2015","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.ejmech.2023.115128_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/jvh.12482","article-title":"Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China","volume":"23","author":"Zhang","year":"2016","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ejmech.2023.115128_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2893.2010.01274.x","article-title":"Management of chronic hepatitis B: experience from China","volume":"17","author":"Sun","year":"2010","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ejmech.2023.115128_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/liv.14364","article-title":"Can we cure hepatitis B virus with novel direct-acting antivirals?","volume":"40","author":"Martinez","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2023.115128_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.12392","article-title":"HBeAg-positive chronic hepatitis B: why do I treat my patients with Nucleos (t) ide Analogs?","volume":"34","author":"Buti","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2023.115128_bib12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2016.05.043","article-title":"Aiming for cure in HBV and HDV infection","volume":"65","author":"Petersen","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib13","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1111\/liv.14607","article-title":"Hepatitis B virus\u2010related hepatocellular carcinoma in the era of antiviral therapy: the emerging role of non-viral risk factors","volume":"40","author":"Li","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2023.115128_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/jvh.13260","article-title":"Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection","volume":"27","author":"Ou","year":"2020","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ejmech.2023.115128_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01032-19","article-title":"Revisiting hepatitis B virus: challenges of curative therapies","volume":"93","author":"Hu","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115128_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.antiviral.2015.10.009","article-title":"Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: search for the \u201cmagic bullet\u201d to kill cccDNA","volume":"123","author":"Zhang","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.virusres.2007.12.024","article-title":"Hepatitis B viruses: reverse transcription a different way","volume":"134","author":"Nassal","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2023.115128_bib19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000371692","article-title":"Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus","volume":"33","author":"Yan","year":"2015","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ejmech.2023.115128_bib20","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1073\/pnas.1730940100","article-title":"Nuclear import of hepatitis B virus capsids and release of the viral genome","volume":"100","author":"Rabe","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115128_bib21","doi-asserted-by":"crossref","first-page":"E4244","DOI":"10.1073\/pnas.1409986111","article-title":"Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses","volume":"111","author":"K\u00f6niger","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115128_bib22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s12250-017-4009-4","article-title":"Recent advances in the study of hepatitis B virus covalently closed circular","volume":"32","author":"Ji","year":"2017","journal-title":"Virol. Sin."},{"key":"10.1016\/j.ejmech.2023.115128_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2004.12.015","article-title":"New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA","volume":"42","author":"Zoulim","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/v9050125","article-title":"A role for the host DNA damage response in hepatitis B virus cccDNA formation\u2014and beyond?","volume":"9","author":"Schreiner","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115128_bib25","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.29133","article-title":"PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation","volume":"66","author":"Zhang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115128_bib26","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00680-17","article-title":"Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants","volume":"61","author":"Lam","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3748\/wjg.v13.i1.48","article-title":"Hepatitis B virus replication","volume":"13","author":"Beck","year":"2007","journal-title":"World J. Gastroenterol.: WJG"},{"key":"10.1016\/j.ejmech.2023.115128_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.patbio.2010.03.005","article-title":"Molecular biology of the hepatitis B virus and role of the X gene","volume":"58","author":"Wei","year":"2010","journal-title":"Pathol. Biol."},{"key":"10.1016\/j.ejmech.2023.115128_bib30","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2023.115128_bib31","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/gtc.12437","article-title":"Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus","volume":"21","author":"Sakuma","year":"2016","journal-title":"Gene Cell."},{"key":"10.1016\/j.ejmech.2023.115128_bib32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.patbio.2009.11.001","article-title":"Pathogenesis of hepatitis B virus infection","volume":"58","author":"Chisari","year":"2010","journal-title":"Pathol. Biol."},{"key":"10.1016\/j.ejmech.2023.115128_bib33","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2023.115128_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrc3892","article-title":"Topoisomerase-mediated chromosomal break repair: an emerging player in many games","volume":"15","author":"Ashour","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115128_bib35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.dnarep.2014.03.020","article-title":"Tyrosyl-DNA-phosphodiesterases (tdp1 and tdp2)","volume":"19","author":"Pommier","year":"2014","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2023.115128_bib36","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature08444","article-title":"A human 5\u2032-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage","volume":"461","author":"Cortes Ledesma","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115128_bib37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1128\/AAC.46.2.425-433.2002","article-title":"Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro","volume":"46","author":"Delmas","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib38","first-page":"1410","article-title":"Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes","volume":"38","author":"K\u00f6ck","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115128_bib39","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra065142","article-title":"Viral hepatitis in HIV infection","volume":"356","author":"Koziel","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115128_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1039\/C3MD00276D","article-title":"Affinity-based target identification for bioactive small molecules","volume":"5","author":"Kawatani","year":"2014","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejmech.2023.115128_bib41","first-page":"535","article-title":"Protein\u2013protein interactions as targets for small molecule drug discovery, Peptide Science","volume":"84","author":"Fry","year":"2006","journal-title":"Orig. Res. Biomol."},{"key":"10.1016\/j.ejmech.2023.115128_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-019-1193-x","article-title":"Lamivudine therapy for chronic hepatitis B in children: a meta-analysis","volume":"16","author":"Luo","year":"2019","journal-title":"Virol. J."},{"key":"10.1016\/j.ejmech.2023.115128_bib43","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2165\/00003495-200363200-00007","volume":"63","author":"Dando","year":"2003","journal-title":"Adefovir dipivoxil, Drugs."},{"key":"10.1016\/j.ejmech.2023.115128_bib44","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2165\/00003495-200666120-00009","volume":"66","author":"Robinson","year":"2006","journal-title":"Entecavir, Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2165\/00003495-200969080-00005","volume":"69","author":"Scott","year":"2009","journal-title":"Entecavir, Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib46","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.2165\/11208510-000000000-00000","volume":"71","author":"Keating","year":"2011","journal-title":"Entecavir, Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib47","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2165\/00003495-200767130-00011","volume":"67","author":"Keam","year":"2007","journal-title":"Telbivudine, Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib48","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2165\/11204330-000000000-00000","volume":"70","author":"Mckeage","year":"2010","journal-title":"Telbivudine, Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2023.115128_bib50","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","article-title":"Tenofovir disoproxil fumarate","volume":"63","author":"Chapman","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib51","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00003495-200565030-00006","article-title":"Tenofovir disoproxil fumarate","volume":"65","author":"Lyseng-Williamson","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib52","article-title":"National institutes of health","volume":"19","author":"Wassner","year":"2020","journal-title":"J. Int. Assoc. Phys. AIDS Care"},{"key":"10.1016\/j.ejmech.2023.115128_bib53","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4254\/wjh.v7.i6.896","article-title":"Lamivudine resistance in children with chronic hepatitis B","volume":"7","author":"Kas\u0131rga","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib54","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2007.03567.x","article-title":"Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine","volume":"27","author":"Manolakopoulos","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115128_bib55","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1128\/AAC.01499-06","article-title":"The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro","volume":"51","author":"Warner","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib56","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0006-2952(97)00189-5","article-title":"Lamivudine (3TC) phosphorylation and drug interactions in vitro","volume":"54","author":"Kewn","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115128_bib57","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/00003495-199753040-00008","volume":"53","author":"Perry","year":"1997","journal-title":"Lamivudine, Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.664794","article-title":"Putative repurposing of lamivudine, a nucleoside\/nucleotide analogue and antiretroviral to improve the outcome of cancer and COVID-19 patients","volume":"11","author":"Garc\u00eda-Trejo","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2023.115128_bib59","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/j.gastro.2007.02.039","article-title":"Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B","volume":"132","author":"Ghany","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115128_bib60","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1053\/jhep.2000.7296","article-title":"Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy","volume":"31","author":"Yeh","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115128_bib61","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen\u2013positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115128_bib62","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/0091270007313325","article-title":"The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection","volume":"48","author":"Sokal","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115128_bib63","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00003495-199958030-00010","volume":"58","author":"Noble","year":"1999","journal-title":"Adefovir dipivoxil, Drugs."},{"key":"10.1016\/j.ejmech.2023.115128_bib64","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"The maze of treatments for hepatitis B","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115128_bib65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/jhep.2000.8626","article-title":"Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants","volume":"32","author":"Perrillo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115128_bib66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115128_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106324","article-title":"Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus","volume":"9","author":"van Hemert","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115128_bib68","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","article-title":"Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation","volume":"141","author":"Fung","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115128_bib69","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1592\/phco.26.12.1745","article-title":"Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection","volume":"26","author":"Sims","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejmech.2023.115128_bib70","first-page":"617","volume":"2","author":"Billich","year":"2001"},{"key":"10.1016\/j.ejmech.2023.115128_bib71","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.46.1.82-88.2002","article-title":"Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication","volume":"46","author":"Marion","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib72","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1128\/JVI.02395-06","article-title":"Inhibition of hepatitis B virus polymerase by entecavir","volume":"81","author":"Langley","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115128_bib73","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1517\/13543784.12.4.683","article-title":"Entecavir: a potent new antiviral drug for hepatitis B","volume":"12","author":"Honkoop","year":"2003","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib74","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1592\/phco.26.12.1745","article-title":"Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection","volume":"26","author":"Sims","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejmech.2023.115128_bib75","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/14789072.2.6.853","article-title":"Entecavir for the treatment of chronic hepatitis B","volume":"2","author":"Shaw","year":"2004","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.ejmech.2023.115128_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-021-03924-0","article-title":"Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models","volume":"12","author":"Clark","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2023.115128_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17746-3","article-title":"Understanding the genetics of viral drug resistance by integrating clinical data and mining of the scientific literature","volume":"12","author":"Goto","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115128_bib78","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"The Telbivudine Phase II Investigator Group, A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen\u2014positive chronic hepatitis B","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115128_bib79","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115128_bib80","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","article-title":"the 018 Study Group, Treatment of Hepatitis B e Antigen\u2013Positive Chronic Hepatitis with Telbivudine or Adefovir: a Randomized Trial","volume":"147","author":"Chan","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2023.115128_bib81","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/TCRM.S5318","article-title":"Safety and efficacy of telbivudine for the treatment of chronic hepatitis","volume":"5","author":"Osborn","year":"2009","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2023.115128_bib82","doi-asserted-by":"crossref","first-page":"E181","DOI":"10.1111\/hepr.12525","article-title":"Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of hepatitis B virus","volume":"46","author":"Liu","year":"2016","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib83","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115128_bib84","first-page":"e37","article-title":"Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B","author":"Wang","year":"2013","journal-title":"J. Viral Hepat.20"},{"key":"10.1016\/j.ejmech.2023.115128_bib85","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115128_bib86","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0149-2918(02)80058-3","article-title":"Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection","volume":"24","author":"Fung","year":"2002","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115128_bib87","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115128_bib88","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"The Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115128_bib90","first-page":"672","article-title":"The GS-US-320-0110 and GS-US-320-0108 Investigators, 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwa","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib91","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib92","first-page":"184","article-title":"Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys?","volume":"18","author":"Aloy","year":"2016","journal-title":"AIDS Rev."},{"key":"10.1016\/j.ejmech.2023.115128_bib93","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1128\/AAC.01152-15","article-title":"In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate","volume":"59","author":"Callebaut","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib94","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/17474124.2017.1386554","article-title":"Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics","volume":"11","author":"Hsu","year":"2017","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib96","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jhep.2020.09.013","article-title":"A global investment framework for the elimination of hepatitis B","volume":"74","author":"Howell","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib97","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ejmech.2023.115128_bib98","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.13635","article-title":"Treatment of hepatitis B: is there still a role for interferon?","volume":"38","author":"Vigan\u00f2","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2023.115128_bib99","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115128_bib100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.14851","article-title":"HBV 2021: new therapeutic strategies against an old foe","volume":"41","author":"Roca Suarez","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2023.115128_bib101","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.06.014","article-title":"Chronic hepatitis B: a wave of new therapies on the horizon","volume":"121","author":"Block","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib102","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115128_bib103","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"Members of the ICE-HBV working groups, ICE-HBV stakeholders group chairs, ICE-HBV senior advisors, zoulim, F.; A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"The Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib104","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2018.06.093","article-title":"Cell and animal models for studying hepatitis B virus infection and drug development","volume":"156","author":"Hu","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115128_bib105","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib106","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/S1386-6532(05)80026-5","article-title":"New targets and inhibitors of HBV replication to combat drug resistance","volume":"34","author":"Cheng","year":"2005","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ejmech.2023.115128_bib107","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.antiviral.2007.12.011","article-title":"The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters","volume":"77","author":"Tseng","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib108","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm034265a","article-title":"Synthesis and antiviral activity of helioxanthin analogues","volume":"48","author":"Yeo","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115128_bib109","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1073\/pnas.0609883104","article-title":"Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue","volume":"104","author":"Ying","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115128_bib110","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.bmc.2009.12.038","article-title":"Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents","volume":"18","author":"Janmanchi","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115128_bib111","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3851\/IMP1686","article-title":"Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture","volume":"21","author":"Ying","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib112","first-page":"366","article-title":"Apoptosis induced by the C21 sterols in Baishouwu and its mechanism of action in hepatoma","volume":"42","author":"Wang","year":"2007","journal-title":"Yao xue xue bao=Acta Pharmaceutica Sinica"},{"key":"10.1016\/j.ejmech.2023.115128_bib113","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2012.05.012","article-title":"Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents","volume":"54","author":"Wang","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115128_bib114","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.antiviral.2013.09.007","article-title":"Antiviral activity of methyl helicterate isolated from Helicteres angustifolia (Sterculiaceae) against hepatitis B virus","volume":"100","author":"Huang","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib115","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jep.2013.09.009","article-title":"Isolation and identification of an anti-hepatitis B virus compound from Hydrocotyle sibthorpioides Lam","volume":"150","author":"Huang","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2023.115128_bib116","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/356806","article-title":"Anti-hepatitis B virus effect and possible mechanism of action of 3, 4-O-dicaffeoylquinic acid in vitro and in vivo","author":"Wu","year":"2012","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.ejmech.2023.115128_bib117","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2016.08.026","article-title":"Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA","volume":"134","author":"Liu","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib118","unstructured":"D. Joseph, R. P. Namboothiri, Molecular docking analysis of natural ligands against infectious proteins of human immunodeficiency virus and hepatitis B virus, Aquinas J. Multidiscip. Res., 60."},{"key":"10.1016\/j.ejmech.2023.115128_bib119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3350\/cmh.2021.0093","article-title":"Toward a complete cure for chronic hepatitis B: novel therapeutic targets for hepatitis B virus","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib120","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/jcm11051349","article-title":"Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives","volume":"11","author":"Taverniti","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2023.115128_bib121","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/v13050770","article-title":"Discovery of new small molecule hits as Hepatitis B virus capsid assembly modulators: structure and pharmacophore-based approaches","volume":"13","author":"Senaweera","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115128_bib122","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S0168-8278(15)30134-3","article-title":"O114: serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-CA","volume":"62","author":"Klumpp","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib123","first-page":"1279A","article-title":"Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"issue":"No. 6","key":"10.1016\/j.ejmech.2023.115128_bib124","first-page":"1385A","article-title":"Phase 1b efficacy and safety of NVR 3-778, a first-in-class HBV core inhibitor, in HBeAg-positive patients with chronic HBV infection","volume":"62","author":"Yuen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115128_bib125","first-page":"931A","article-title":"Pharmacokinetics (PK) and PK modeling of the first-in-class HBV core inhibitor NVR 3-778 dosed once-(QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients witn chronic HBV infection (CHBV)","volume":"64","author":"Kakuda","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115128_bib126","first-page":"1","article-title":"Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115128_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.04.005","article-title":"Safety and efficacy of vebicorvir administered with entecavir in treatment-na\u00efve patients with chronic hepatitis B virus infection","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"The lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib129","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01463-20","article-title":"Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731","volume":"64","author":"Huang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/liv.14837","article-title":"Hepatitis B cure: how and when","volume":"41","author":"Dusheiko","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2023.115128_bib131","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciaa961","article-title":"Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115128_bib132","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01686-19","article-title":"A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single-and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers","volume":"64","author":"Zhao","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib133","author":"Pavlova","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2023.115128_bib134","doi-asserted-by":"crossref","DOI":"10.1080\/14728214.2022.2074977","article-title":"Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs at phase II clinical trials","author":"Hui","year":"2022","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib135","first-page":"503A","article-title":"The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype AH clinical isolates in vitro","volume":"66","author":"Berke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115128_bib136","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02439-19","article-title":"Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379","volume":"64","author":"Berke","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib137","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115128_bib138","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/jac\/dkaa179","article-title":"Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A\u2013H clinical isolates and core site-directed mutants in vitro","volume":"75","author":"Verbinnen","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib139","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1007\/s12325-019-01017-1","article-title":"Pharmacokinetics, safety and tolerability of JNJ-56136379, a novel hepatitis B virus capsid assembly modulator","volume":"36","author":"Vandenbossche","year":"2019","journal-title":"healthy Subj. Adv. Ther."},{"key":"10.1016\/j.ejmech.2023.115128_bib140","article-title":"Identification of compounds targeting hepatitis B virus core protein dimerization through a split luciferase complementation assay","volume":"62","author":"Mani","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib141","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S0618-8278(19)30936-3","article-title":"FRI-191-EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo","volume":"70","author":"Vaine","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib142","first-page":"504A","volume":"74","author":"Feld","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115128_bib143","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/jvh.13425","article-title":"What drives the dynamics of HBV RNA during treatment?","volume":"28","author":"Gon\u00e7alves","year":"2021","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ejmech.2023.115128_bib144","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","article-title":"Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial","volume":"6","author":"Yuen","year":"2021","journal-title":"The Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib145","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2468-1253(21)00256-9","article-title":"The potential immune regulation benefit of CpAMs beyond HBV suppression","volume":"6","author":"Wu","year":"2021","journal-title":"The Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib146","first-page":"697","article-title":"Painkilling anti-NGF antibodies stage phase III comeback","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115128_bib147","first-page":"e01701","article-title":"Novel hepatitis B virus capsid assembly modulator induces potent antiviral responses in vitro and in humanized mice","volume":"64","author":"Amblard","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib148","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/v13010114","article-title":"Studies on the efficacy, potential cardiotoxicity and monkey pharmacokinetics of GLP-26 as a potent hepatitis B virus capsid assembly modulator","volume":"13","author":"Hurwitz","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115128_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112714","article-title":"Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies","volume":"206","author":"Ren","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115128_bib150","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1021\/acs.jmedchem.1c02040","article-title":"The mechanism of action of hepatitis B virus capsid assembly modulators can Be predicted from binding to early assembly intermediates","volume":"65","author":"Pavlova","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115128_bib151","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bcp.2018.04.020","article-title":"A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity","volume":"154","author":"Pan","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115128_bib152","first-page":"1","article-title":"SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88","volume":"37","author":"Li","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib153","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/cells9010207","article-title":"The immuno-modulatory effects of inhibitor of apoptosis protein antagonists in cancer immunotherapy","volume":"9","author":"Michie","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.115128_bib154","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.7150\/thno.21717","article-title":"XIAP limits autophagic degradation of Sox2 and is a therapeutic target in nasopharyngeal carcinoma stem cells","volume":"8","author":"Ji","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2023.115128_bib155","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1021\/acs.jmedchem.8b01668","article-title":"Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: current status and perspectives","volume":"62","author":"Cong","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115128_bib156","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.3390\/cancers13112618","article-title":"Therapeutics targeting the core apoptotic machinery","volume":"13","author":"Hamilton","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115128_bib157","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3748\/wjg.v27.i21.2727","article-title":"Toward a new era of hepatitis B virus therapeutics: the pursuit of a functional cure","volume":"27","author":"Tsounis","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2023.115128_bib158","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2147\/DDDT.S309964","article-title":"Analysis of clinical trials of new drugs for liver diseases in China","volume":"15","author":"Lin","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2023.115128_bib159","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2174\/1389557520666200212105417","article-title":"Anticancer agents based on vulnerable components in a signalling pathway","volume":"20","author":"Vaidya","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115128_bib160","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/cmdc.201900410","article-title":"Bivalent SMAC mimetics for treating cancer by antagonizing inhibitor of apoptosis proteins","volume":"14","author":"Zhu","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115128_bib161","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/cells9020406","article-title":"Future therapeutic directions for Smac-mimetics","volume":"9","author":"Morrish","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.115128_bib162","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217433","article-title":"The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice","volume":"14","author":"Gallay","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115128_bib163","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1021\/acs.orglett.1c00881","article-title":"Semisynthesis of CRV431","volume":"23","author":"Li","year":"2021","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2023.115128_bib164","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13543784.2020.1703948","article-title":"Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Ure","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2023.115128_bib165","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/v13061169","article-title":"Novel antivirals in clinical development for chronic hepatitis B infection","volume":"13","author":"Mak","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115128_bib166","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14656566.2018.1560424","article-title":"Efficacy and safety of alisporivir for the treatment of hepatitis C infection","volume":"20","author":"Stanciu","year":"2019","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115128_bib167","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.119.261099","article-title":"A pan-cyclophilin inhibitor, CRV431, decreases fibrosis and tumor development in chronic liver disease models","volume":"371","author":"Kuo","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115128_bib168","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237236","article-title":"Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice","volume":"15","author":"Bobardt","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115128_bib169","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/cells8111409","article-title":"Evaluation of NV556, a novel cyclophilin inhibitor, as a potential antifibrotic compound for liver fibrosis","volume":"8","author":"Sim\u00f3n Serrano","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.115128_bib170","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/1759-7714.12548","article-title":"Cyclophilin A promotes non-small cell lung cancer metastasis via p38 MAPK","volume":"9","author":"Guo","year":"2018","journal-title":"Thorac. cancer"},{"key":"10.1016\/j.ejmech.2023.115128_bib171","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3390\/v13112309","article-title":"How influenza A virus NS1 deals with the ubiquitin system to evade innate immunity","volume":"13","author":"Lamotte","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115128_bib172","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1093\/nar\/gkg881","article-title":"Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors","volume":"31","author":"Klumpp","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib173","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.antiviral.2013.06.007","article-title":"beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity","volume":"99","author":"Hu","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib174","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2019.02.005","article-title":"Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors","volume":"164","author":"Edwards","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115128_bib175","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01460-21","article-title":"Efficient inhibition of hepatitis B virus (HBV) replication and cccDNA formation by HBV ribonuclease H inhibitors during infection","volume":"65","author":"Chauhan","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115128_bib176","first-page":"106","article-title":"Cytomegalovirus hepatitis in immunocompetent and immunocompromised hosts","volume":"9","author":"Da","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115128_bib177","doi-asserted-by":"crossref","first-page":"424","DOI":"10.14218\/JCTH.2020.00046","article-title":"Macrophage phenotypes and hepatitis B virus infection","volume":"8","author":"Li","year":"2020","journal-title":"J. Clin. Transl. Hepatol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T16:14:28Z","timestamp":1737303268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":177,"alternative-id":["S0223523423000430"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115128","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of the development of HBV small molecule inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115128"}}